Join Industry and Global Regulatory Representatives to Discuss Advances in Oligonucleotide Science

For the past 4 years DIA/FDA has convened industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. The 2012 event will continue to address bioinformatics, microRNAs, delivery methods, impurity issues, metabolism, non-clinical assessments in support of drug development and clinical advances in therapeutic targets, trial design and safety. This conference will also incorporate dialogue to address RNA interference technologies and expand clinical pharmacology representation in discussions of the emerging technologies being developed in the field of oligonucleotide-based therapeutics.

FEATURED TOPICS:
• Non-clinical
• Chemistry, Manufacturing, and Controls (CMC)
• Clinical Development
• Oligonucleotide Safety Working Group Updates

WHO SHOULD ATTEND
Chief Scientific Officers, Vice Presidents, Directors, Senior Management, Group/Team/Project Leaders, Scientists, Investigators and Researchers working in the following areas:
• Biotechnology
• Biologics
• Clinical Research
• Chemistry, manufacturing and control
• Clinical, regulatory, and business development
• Delivery technologies
• Drug discovery
• Preclinical
• Quality assurance
• RNAi
• Vaccines
CONTINUING EDUCATION CREDITS

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Drug Information Association. PIM is accredited by the ACCME to provide continuing medical education for physicians.

See attached amendment for CME Credit Statement and details.

Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer 1.4 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

If you would like to receive a statement of credit, you must attend the program, sign-in at the DIA registration desk each day of the program, and complete the online credit request process through My Transcript at www.diahome.org. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on May 2, 2012.

This program is part of DIA’s Certificate Program and is awarded the following:
• Clinical Research Certificate Program: 10 Elective Units
For more information go to www.diahome.org/certificateprograms

Learning Objectives
At the conclusion of this meeting, participants should be able to:
• Identify accomplishments and challenges in the clinical development of oligonucleotide-based therapeutic drugs
• Describe the critical issues in the nonclinical development of oligonucleotides and the efforts by industry and regulatory authorities to address the unmet needs
• Differentiate the chemistry, manufacturing and controls challenges associated with the development of synthetic oligonucleotides, including formulations
• Explain unique aspects in the development of oligonucleotide-based therapeutics and the various scientific approaches to address each
• Recognize the achievements made in the field to date and share the vision of the benefits to patients that are possible

Disclosure Policy
The Postgraduate Institute for Medicine (PIM) and DIA require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and DIA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

KEYNOTE SPEAKERS

Paul C. Brown, PhD
ODE Associate Director for Pharmacology and Toxicology
CDER, FDA

Dr. Brown is an Associated Director of Pharmacology and Toxicology in the Center for Drug Evaluation and Research at the FDA. He has been at the FDA since 1996 when he joined the Division of Dermatology and Dental Drug Products as a Pharmacology/Toxicology reviewer. He was supervisor for Pharmacology/Toxicology in this Division from 2003 to 2008. Prior to coming to the FDA he was a Pharmacology Research and Training Fellow in the National Cancer Institute from 1991 to 1996. He received his PhD in toxicology from the University of Maryland in 1991. Dr. Brown is also co-chair of CDER’s Pharmacology/Toxicology Coordinating Committee Subcommittee on oligonucleotides.

C. Frank Bennett, PhD
Senior Vice President, Research
Isis Pharmaceuticals

Dr. Bennett is Senior Vice President of Research at Isis Pharmaceuticals. He is responsible for preclinical antisense drug discovery and antisense technology research. Dr. Bennett is one of the founding members of the Company. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery and pharmacokinetics. He also runs the Company’s antisense mechanism program which is focused on the development of RNase H, RNAi, micro-RNA and splicing. Dr. Bennett has published more than 130 papers in the field of antisense research and development and has more than 120 issued U.S. patents.

Prior to joining Isis, Dr. Bennett was Associate Senior Investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories, GlaxoSmithKline (currently, GlaxoSmithKline).

Dr. Bennett received his PhD in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. Dr. Bennett performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories, where he studied the signal transduction pathway of leukotrienes. Dr. Bennett serves on the Advisory Board for the Experimental Therapeutics Centre in Singapore and the Scientific Committee for the American Society of Gene and Cell Therapy.
SESSION 2A: NON-CLINICAL TRACK

Updates from Oligonucleotide Safety Working Group (OSWG) and 2011 National Institutes of Health (NIH)-RAC Conference on RNA Oligonucleotides

SESSION CHAIRPERSON:
David H. Schubert
Vice President of Regulatory Affairs & Quality Assurance
MediVector, Inc.

Jim Zisek
Director, Third Party Alliances
CMC Global Regulatory Affairs
GlaxoSmithKline

Update on ICH Q11
Betsy Fritschel
Director, Enterprise Regulatory Compliance
Johnson & Johnson

A Control Strategy for Raw Materials of Oligonucleotide Drug Substances
Claus Rentel, PhD
Director, Analytical Development and Quality Control
Isis Pharmaceuticals, Inc

Establishing a Raw Material Supply Chain for the Lifecycle of Oligonucleotide Medicines – A Focus on Quality and Scalability
Michael Webb, PhD
Vice President API Chemistry & Analysis
GlaxoSmithKline

SESSION 2B: CMC TRACK

Oligonucleotide Drug Substance Raw Materials: Quality Requirements and Other Challenges

SESSION CHAIRPERSON
Daren Levin, PhD
Senior Scientific Investigator
Exploratory Development Sciences
GlaxoSmithKline

Update on ICH Q11
Betsy Fritschel
Director, Enterprise Regulatory Compliance
Johnson & Johnson

A Control Strategy for Raw Materials of Oligonucleotide Drug Substances
Claus Rentel, PhD
Director, Analytical Development and Quality Control
Isis Pharmaceuticals, Inc

SESSION 2C: CLINICAL TRACK

Clinical Advances in Oligonucleotide Drugs and Therapeutics

SESSION CHAIRPERSON
Akshay K. Vaishnaw, MD, PhD
Senior Vice President and Chief Medical Officer
Alnylam Pharmaceuticals, Inc.

Clinical Progress with RNAi Therapeutics

Akshay Vaishnaw, MD, PhD
Senior Vice President and Chief Medical Officer
Alnylam Pharmaceuticals, Inc.

Quark Pharmaceuticals siRNA Clinical Development Program in Ophthalmic Indications

Rabia Ozden, MD
Executive Medical Director, Ophthalmology
Quark Pharmaceuticals, Inc.
### SESSION 3A: NON-CLINICAL TRACK

**Bioanalytical and Clinical Pharmacology Issues**

**Session Chairperson**
Pengfei Song, PhD  
Clinical Pharmacology Reviewer  
Office of Clinical Pharmacology (OCP)  
Division of Clinical Pharmacology 5  
CDER, FDA

**Oligonucleotide Bioanalysis: Sensitivity vs Specificity**

Laixin Wang, PhD  
Tandem Labs  
LabCorp  
Method Development Group Leader

**The Role of PKPD in the Development of Oligonucleotides**

Huiping Xu, PhD  
Associate Director, Clinical Pharmacology  
Oncology Business Unit  
Pfizer, Inc

**Regulatory Considerations on the Clinical Pharmacology of the Oligonucleotide-based Drug Products**

Pengfei Song, PhD  
Clinical Pharmacology Reviewer  
Office of Clinical Pharmacology (OCP)  
Division of Clinical Pharmacology 5  
CDER, FDA

**Bridging Non-clinical to Clinical**

John Grundy, PhD  
Vice President, Pharmacokinetics (PK) and Clinical Pharmacology  
Isis Pharmaceuticals

---

### SESSION 3B: CMC TRACK

**Managing Change During Development**

**Session Chairperson**
G. Susan Srivatsa, PhD  
President  
ElixinPharma

**Managing Site and Process Changes during Clinical Development**

Lubomir V. Nechev, PhD  
Senior Director, Process Chemistry  
Alnylam Pharmaceuticals, Inc.

**Managing Process Change through Development and Scale-Up of Oligonucleotide APIs**

Paul Metz  
Senior Director, Manufacturing Operations  
Agilent Technologies, Inc.

**Panel Discussion**

**Moderator:** G. Susan Srivastaa  
**Panelists:**  
Ramesh Raghavachari  
Lubo Nechev  
Paul Metz  
Claus Rentel  
Mike Webb

---

### SESSION 3C CLINICAL TRACK

**Oncology**

**Session Chairperson**
Hubert Heinrichs, MD, MBA  
Chief Medical Officer and Acting Chief Executive Officer  
Antisense Pharma GMBH

**Trabedersen is Highly Effective Against TGF-beta 2 and Shows High Efficacy and Tolerability in Several Cancer Indications**

Hubert Heinrichs, MD, MBA  
Chief Medical Officer and Acting Chief Executive Officer  
Antisense Pharma GMBH

**Update on Phase 1 Trial of ALN-VSP for Patients with Advanced Cancer with Liver Involvement**

Jared Gollob, MD  
Senior Director of Clinical Research  
Alnylam Pharmaceuticals

**New Medicine to Treat Various Types of Cancer: Encouraging Clinical Phase I Atu027 Data**

Klaus Giese, PhD  
Chief Scientific Officer  
Silence Therapeutics AG
### SESSION 4A: NON-CLINICAL TRACK

**Immune Response**

**SESSION CHAIRPERSONS**

- Peyton Myers, PhD  
  Pharmacologist  
  Division of Antiviral Products  
  CDER, FDA  

- Scott Henry, PhD, DABT  
  Vice President, Toxicology  
  Isis Pharmaceuticals, Inc.  

**Update from the OSWG Immunomodulation Subcommittee**

- Rosanne Seguin, PhD  
  Former Director Immunology and Development Support at Topigen  
  Part of the Pharmaxis Group  
  Topigen Pharmaceuticals  

**Effects of Chronic Low Level Complement Activation**

- Scott Henry, PhD, DABT  
  Vice President, Toxicology  
  Isis Pharmaceuticals Inc.  

**Topic Pulmonary Indications for Inhaled Oligonucleotides**

- Nicolay Ferrari, PhD  
  Director Pharmacology  
  Topigen Pharmaceuticals  

**Regulatory Perspective on Immunostimulation Concerns**

- Renqin Duan, PhD  
  Toxicologist  
  Division of Dermatology and Dental Products  
  CDER, FDA  

**SESSION 4B: CMC TRACK**

**Specification and Impurities**

**Challenges in the Development of Synthetic Oligonucleotide Drug Substances**

**SESSION CHAIRPERSON**

- Rao Kambhampati, PhD  
  Senior Regulatory Review Scientist  
  Branch V  
  Division of New Drug Quality Assessment II  
  CDER, FDA  

**ICH and Oligonucleotides**

- James V. McArdle, PhD  
  McArdle and Associates, LLC  

**A White Paper on Specifications for Oligonucleotide Active Pharmaceutical Ingredients (APIs)**

- Bob Sharma, MBA, PhD  
  Vice President, Process Development & Manufacturing  
  Oncology Division  
  Geron Corporation  

**Progress on the Preparation of a White Paper Addressing Impurities in Oligonucleotide APIs**

- Kathy Ackley, PhD, RAC  
  Vice President Development & Project Management  
  Girindus America, Inc.  

**Panel Discussion**

- **Moderator: Rao Kambhampati**  
  **Panelists:**  
  Bob Sharma  
  Jim McArdle  
  Kathy Ackley  
  Rene Thurmer  
  Ipsita Roymoulik  

### SESSION 4C: CLINICAL TRACK

**Neuromuscular**

**SESSION CHAIRPERSON**

- Giles Campion, MD  
  Chief Medical Officer and Senior Vice President, Research and Development  
  Prosensa  

**AVI Biopharma’s Drug Therapeutic Candidates with Duchene Muscular Dystrophy (DMD)**

- Ed Kaye, MD  
  Chief Medical Officer  
  AVI Biopharma  

**Results of Prosensa’s Extended Phase I/II Exon-skipping Trial in Duchenne**

- Giles Campion, MD  
  Chief Medical Officer and Senior Vice President, Research and Development  
  Prosensa  

**Intrathecal Delivery of ASOs for ALS and SMA**

- Kathie Bishop, PhD  
  Director, Clinical Development  
  Isis Pharmaceuticals  

**Audience Questions and Discussion**

---

**5:00-6:00 PM NETWORKING RECEPTION**
### SESSION 5A AND 5C: JOINT CLINICAL AND NON-CLINICAL TRACK

**Renal and Hepatic Safety Issues (Joint w/Clinical)**  
**SESSION CHAIRPERSONS**  
Shwu-Luan Lee, PhD  
Pharmacology/Toxicology Reviewer  
CDER, FDA  
Giles Campion, MD  
Chief Medical Officer and Senior Vice President, Research and Development  
Prosensa  

**Alnylam’s VSP02 Program: Translation of Nonclinical to Clinical**  
Garvin Warner, PhD  
Vice President, Preclinical Development  
Alnylam Pharmaceuticals  

**Hepatotoxicity of Oligonucleotides: Is There Relationship Between Non-clinical and Clinical Responses?**  
Yann Tessier, PhD  
Director, Non Clinical Development  
Santaris Pharmaceuticals  

**Comparison of Non-clinical & Clinical Safety Data of Synthetic siRNAs for Renal Diseases Following IV Administration**  
James D. Thompson, PhD  
Vice President  
Quark Pharmaceuticals, Inc.  

**Renal Tolerability of 2’MOE Antisense Oligonucleotides and The Role of Drug Accumulation**  
Husam Younis, PhD  
Toxicology Research Pharmacist  
Isis Pharmaceuticals  

**SESSION 5B: CMC TRACK**

Bioassay Challenges, Novel Excipients and Novel Delivery Systems  
**SESSION CHAIRPERSON**  
Jim Zisek  
Director, Third Party Alliances  
Global CMC Regulatory Affairs  
GlaxoSmithKline  

Regulatory Considerations on Complex Formulations - Novel Excipient, Performance Requirement and Bioassay Issues  
René Thürmer, PhD  
Deputy Head Unit Pharmaceutical Biotechnology BfArM – Federal Institute for Drugs and Medical Devices, Germany  

Novel Particulate Delivery Systems and Potential CMC Development Challenges  
Pallav Bulsara, PhD  
Formulation Scientist (Investigator)  
GlaxoSmithKline  

Lessons from Biological Therapeutics - Developing, Validating and Maintaining a Potency Bioassay  
Sally Seaver, PhD  
Founder and President  
Seaver Associates, LLC  

Audience Questions and Discussion  

---

### 10:00-10:30 AM REFRESHMENT BREAK

---

### 10:30-11:15 AM POSTER PRESENTATION AND GROUP DISCUSSION (AUTHORS WILL BE AVAILABLE DURING THIS TIME TO ANSWER QUESTIONS)

---

### 11:15 AM-12:00 PM SESSION 6

**Keynote Address: Introduction**  
Saraswathy (Sara) V. Nochur, PhD  
Vice President, Regulatory Affairs  
Alnylam Pharmaceuticals, Inc.  

**Keynote Speaker Presentation**  
Antisense Technology: Past, Present and Future  
C. Frank Bennett, PhD  
Senior Vice President, Research  
Isis Pharmaceuticals
### SESSION 7A AND 7B: JOINT NON-CLINICAL AND CMC TRACK

**Bridging Formulation Changes during Development. Panel Discussion on Future Approaches**

**Session Chairpersons-CMC**

**Jim Zisek**  
Director, Third Party Alliances  
Global CMC Regulatory Affairs  
GlaxoSmithKline

**Analytical and Pre-Clinical Considerations in Assessing Comparability of Complex Formulations**

**Anthony Leone, PhD**  
Associate Director at Merck  
Research Fellow  
Merck

**Product Development with Rapidly Evolving Platform Technologies: Strategies for Integrating Recent Results in Ongoing Product Development Efforts**

**Amy Lee**  
Research Director  
Tekmira Pharmaceuticals

**Panel Discussion**

**Panelists:**  
Amy Lee  
Jian Wang  
Anthony Leone  
Scott Barros  
Rao Kambhampati

---

### SESSION 7C: CLINICAL TRACK

**Liver/Kidney**

**Session Chairperson**

**Martin S. Polinsky, MD**  
Executive Medical Director, Cardio-Renal Program  
Quark Pharmaceuticals, Inc.

**Systemic Administration of Non-formulated Synthetic siRNAs: Initial Results From Early-phase Clinical Trials in Acute Kidney Injury**

**Martin S. Polinsky, MD**  
Executive Medical Director, Cardio-Renal Program  
Quark Pharmaceuticals, Inc.

**Miravirsen (MIR), an Oligonucleotide Targeting miR-122, Produced Long-lasting Suppression of HCV RNA in Treatment Naïve Patients with Genotype 1 (GT1) Chronic HCV Infection**

**Michael R. Hodges, MD, MBBS**  
Chief Medical Officer  
Santaris Pharma A/S

**Phase I /Ib Clinical Data of NOX-E36, A Mirror-image RNA Oligonucleotide for the Treatment of Diabetic Nephropathy**

**Sven Klussmann, PhD**  
Chief Scientific Officer  
NOXXON Pharma AG

**Audience Questions and Discussion**
### SESSION 8A: NON-CLINICAL TRACK

**Non-clinical Hot Topics**

**Session Chairpersons**

**Jim Wild**
Pharmacologist  
Division of Anti-infective Products  
CDER, FDA

**Arthur Levin, PhD**
Vice President and Chief Development Officer  
Santaris Pharma a/s

**Selective De-repression of Gene Expression by Targeting Long Non-coding RNA with Olidonucleotides**

**Art Krieg, PhD**
Atlas Venture  
Formerly Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit

**Issues with Development of miRNA and Non-coding RNAs**

**Aimee Jackson, PhD**
Inventive Molecular Biologist  
Consultant

**miRNAs in Cardiovascular Disease & Issues in Development**

**Eva van Rooij, PhD**
Senior Director of Biology  
miRagen Therapeutics, Inc.

**Audience Questions and Discussion**

### SESSION 8B: CMC TRACK

**Recent Advances in Formulation Strategies**

**Session Chairperson**

**Gregory E. Hardee, PhD**
Senior Pharmaceutical Consultant  
OligoDevelopment.com

**Aptamer-mediated Delivery of Therapeutic Oligonucleotides**

**Bruce Sullenger, PhD**
Joseph and Dorothy Beard Professor  
Director of the Duke Center for Translational Research  
Department of Surgery  
Duke Translational Institute of Medicine (DTMI)  
Duke University Medical Center

**Oral Delivery of Nucleic-acid Based Therapeutics**

**Gregory E. Hardee, PhD**
Senior Pharmaceutical Consultant  
OligoDevelopment.com

**A Pro-drug Approach for the Delivery of Oligonucleotides**

**Nick Hammond, PhD**
Chief Technology Officer  
Ablitech

**Audience Questions and Discussion**

### SESSION 8C: CLINICAL TRACK

**Cardiopulmonary**

**Session Chairperson**

**Christopher P. Rusconi, PhD**
Chief Scientific Officer  
Regado Biosciences, Inc

**Clinical Development Advances in Cardiovascular Medicine: A Portfolio Review**

**Richard S. Geary, PhD**
Senior Vice President, Development  
Isis Pharmaceuticals, Inc.

**Subcutaneous Administration of the Coagulation FIXa Inhibitor Pegnivacogin (aka RB006) Provides Prolonged, Stable Anticoagulation Reversible by Anivamersen (aka RB007)**

**Christopher P. Rusconi, PhD**
Chief Scientific Officer  
Regado Biosciences, Inc

**ASM8 for the Treatment of Asthma: A Clinical Update**

**Nicolay Ferrari, PhD**
Director Pharmacology  
Topigen Pharmaceuticals

**Audience Questions and Discussion**
DAY 3 | WEDNESDAY, APRIL 18, 2012

7:30-9:00 AM  REGISTRATION AND CONTINENTAL BREAKFAST

9:00-10:00 AM  SESSION 9

Plenary Session: The Evolution of Pharma and Venture Capital Perspectives on Oligonucleotides Therapeutics

Art Krieg, PhD  
Atlas Venture  
Formerly, Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit

10:00-10:30 AM  REFRESHMENT BREAK

10:30 AM-12:00 PM  SESSION 10 PANEL DISCUSSION AND PATH FORWARD

This panel discussion is meant to highlight the challenges and issues with the development of oligonucleotide-based products in general and as brought forth at this conference. The intention is to transform this discussion into action-oriented objectives to address the regulatory and industry issues and challenges affecting us all.

Panel Facilitators and Discussants

**Non-Clincal Track**

Arthur Levin, PhD  
Vice President and Chief Development Officer  
Santaris Pharma a/s

Doug Kornbrust, PhD  
President  
Preclinsight

**CMC Track**

Jim Zisek  
Director, Third Party Alliances  
Global CMC Regulatory Affairs  
GlaxoSmithKline

René Thürmer, PhD  
Unit Pharmaceutical Biotechnology BfArM  
Federal Institute for Drugs and Medical Devices, Germany

**Clinical Track**

James D. Thompson, PhD  
Vice President, Pharmaceutical Development  
Quark Pharmaceuticals, Inc.

Saraswathy (Sara) V. Nochur, PhD  
Vice President, Regulatory Affairs  
Alnylam Pharmaceuticals, Inc

12:15 PM  CLOSING REMARKS

David H. Schubert  
Vice President of Regulatory Affairs & Quality Assurance  
MediVector, Inc.

Jim Zisek  
Director, Third Party Alliances  
CMC Global Regulatory Affairs  
GlaxoSmithKline

12:30 PM  WORKSHOP ADJOURNED
Payment options: Register online at www.diahome.org or check payment method.

☐ CREDIT CARD number may be faxed to +1.215.442.6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

☐ Visa ☐ MC ☐ AMEX Exp Date

Card # ____________________________
Name (printed) ________________________________
Signature ________________________________

☐ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

☐ BANK TRANSFER When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

TRAVEL AND HOTEL

The most convenient airport is Ronald Reagan Washington National Airport - DCA and attendees should make airline reservations as early as possible to ensure availability. The Washington Marriott Metro Center is holding a block of rooms at the reduced rate below until March 25, 2012, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $269 Double $269

Please contact the Washington Marriott Metro Center by telephone at 202.737.2200 or 1-202-347-5886 and mention the DIA event. The hotel is located at 775 12th Street NW, Washington, District Of Columbia 20005 USA

CANCELLATION POLICY: On or before APRIL 09, 2012

Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academia or Nonprofit (Member or Nonmember) = $100
Tutorial (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Participants with Disabilities: DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.

EVENT INFORMATION

For registration questions, please contact Elizabeth Espich by phone at +1.215.293.5802 or by email at Elizabeth.Espich@diahome.org.

For agenda details, please contact Program Manager Joanne Wallace by phone at +1.215.442.6180 or by email at Joanne.Wallace@diahome.org.